BIOG vs. CTUK, ANII, HNE, AAIF, BIPS, AUSC, TAM, HINT, CTPE, and LWI
Should you be buying Biotech Growth stock or one of its competitors? The main competitors of Biotech Growth include CT UK Capital and Income (CTUK), abrdn New India Investment Trust (ANII), Henderson EuroTrust (HNE), abrdn Asian Income Fund (AAIF), Invesco Bond Income Plus (BIPS), abrdn UK Smaller Companies Growth Trust (AUSC), Tatton Asset Management (TAM), Henderson International Income (HINT), CT Private Equity Trust (CTPE), and Lowland (LWI). These companies are all part of the "asset management" industry.
Biotech Growth (LON:BIOG) and CT UK Capital and Income (LON:CTUK) are both small-cap financial services companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.
In the previous week, Biotech Growth's average media sentiment score of 0.00 equaled CT UK Capital and Income'saverage media sentiment score.
Biotech Growth received 82 more outperform votes than CT UK Capital and Income when rated by MarketBeat users.
Biotech Growth has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, CT UK Capital and Income has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
CT UK Capital and Income's return on equity of -1.08% beat Biotech Growth's return on equity.
CT UK Capital and Income has higher revenue and earnings than Biotech Growth. CT UK Capital and Income is trading at a lower price-to-earnings ratio than Biotech Growth, indicating that it is currently the more affordable of the two stocks.
26.7% of Biotech Growth shares are held by institutional investors. Comparatively, 83.4% of CT UK Capital and Income shares are held by institutional investors. 0.5% of Biotech Growth shares are held by insiders. Comparatively, 0.4% of CT UK Capital and Income shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
CT UK Capital and Income beats Biotech Growth on 7 of the 11 factors compared between the two stocks.
Get Biotech Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Biotech Growth Competitors List
Related Companies and Tools